Delayed-onset neutropenia with divalproex sodium

Annals of Pharmacotherapy

Volumn 42, Issue 10, 2008, Pages 1507-1510

  Stoner, Steven C ^a,c   Deal, Eli ^b   Lurk, Jason T ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c Northwest Missouri Psychiatric Rehabilitation Center   (United States)

Author keywords

Divalproex; Hematology; Neutropenia; Valproic acid

Indexed keywords

OLANZAPINE; TOPIRAMATE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; BORDERLINE STATE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HUMAN; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; TREMOR;

ANTICONVULSANTS; BLOOD CELL COUNT; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; VALPROIC ACID;

EID: 52949101031     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L239     Document Type: Article

References (19)

1. Strakowski SM, DelBello MP, Adler CM. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 2001;15:701-18.
2. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003;37(suppl):S25-42.
3. Eadie MJ, Hooper WD, Dickinson RG. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol Adverse Drug Exp 1988;3:85-106.
4. Blackburn SC, Oliart AD, Garcia Rodriguez LA, Perez G. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998;18:1277-83.
5. Barr RD, Copeland SA, Stockwell ML, Morris N, Kelton JC. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982;57:681-4.
6. Watts R, Emanuel P, Zuckerman K, Howard T. Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J Pediatr 1990;117:495-9.
7. Tohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995;152:413-8.
8. Pantelis C, Adesanya A. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z J Psychiatry 2001;35:544-5.
9. Vesta KS, Medina PJ. Valproic acid-induced neutropenia. Ann Pharmacother 2003;37:819-21. Epub 23 Apr 2003. DOI 10.1345/aph.1C381
10. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000;22:62-5.
11. Jaeken J, van Goethem C, Casaer P, Devlieger H, Eggermont E, Pilet M. Neutropenia during sodium valproate treatment. Arch Dis Child 1979;54:986-7.
12. Symon D, Russell G. Sodium valproate and neutropenia (letter). Arch Dis Child 1983;58:235.
13. Petros WP, Eiricson S. Hematopoiesis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 6th ed. New York: McGraw-Hill, 2005:1793-804.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
15. Gajwani P, Tesar G. Olanzapine-induced neutropenia. Psychosomatics 2000;4:150-1.
16. Steinwachs A, Grohmann R, Pedrosa F, Ruther E, Schwerdtner I. Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry 1999;32:154-6.
17. Konakanchi R, Grace J, Szarowicz R, Pato M. Olanzapine prolongation of granulocytopenia after clozapine discontinuation. J Clin Psychopharmacol 2000;20:703-4.
18. Sayin A, Cosar B. Prolongation of clozapine-induced leucopenia with olanzapine treatment. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:958-9.
19. O'Connor C, Schraeder P, Kurland A, O'Connor W. Evaluation of the mechanisms of antiepileptic drug-related chronic leukopenia. Epilepsia 1994;35:149-54.